ATLAS fair value
ATLAS has no fair value for this stock today.
Maze Therapeutics stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · NASDAQ
Prices as of Oct 27, 2026 · USD
ATLAS has no fair value for this stock today.
47%
that it ends higher than today in 21 sessions
ATLAS's own quantitative analysis, all in one place.
Plans from €3.99 a month.
ATLAS's model gives Maze Therapeutics a 47% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between $27.90 and $35.06; in 9 out of 10, between $22.79 and $42.93. Estimated annual volatility is 70%.
ATLAS does not publish a fair value for MAZE right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks MAZE has traded between $21.95 and $53.65. Today it is 41.0% below that high and 44% above its low.
Its beta is 0.00: it tends to move less than the market.
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule precision medicines for kidney, cardiovascular, and related metabolic diseases, including obesity.
Want to see everything about Maze Therapeutics?
Get started →Plans from €3.99 a month.
Other companies in the same line of business:
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule precision medicines for kidney, cardiovascular, and related metabolic diseases, including obesity.
47%: close to a coin flip. In half of the simulated outcomes, MAZE ends the month between $27.90 and $35.06.
Maze Therapeutics's market capitalization is $1.5B. We do not show a P/E because it has no positive earnings to base one on.
ATLAS estimates annual volatility at 70%. In a typical month, half of the outcomes end between $27.90 and $35.06.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer
ATLAS Signals
The week in the market, three stocks on ATLAS’s radar and what comes next. Get it every Monday.
By subscribing you agree to receive ATLAS Signals by email every Monday. You can unsubscribe with one click at any time. Privacy